Most Read Articles
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
11 Nov 2016
Non-purulent cellulitis and cutaneous abscesses, despite both belonging to the spectrum of skin and soft-tissue infections, are aetiologically different, a new study reports. Further, atypical bacteria may be present in cellulitis patients, indicating novel disease mechanisms.
05 Jan 2017
Olumacostat glasaretil (OG) appears to be effective and is well tolerated in patients with moderate to severe facial acne vulgaris, suggesting the need for further development, according to a new study.
Tristan Manalac, 10 Mar 2018
Cost of treatment is a major driver of patients’ primary nonadherence to acne medication, according to a recent study. Physicians who openly discuss medications costs and provide a plan of action in case patients are unable to fill prescriptions may improve treatment adherence.

Anti-TNF agents may contribute to increased risk of psoriasiform diseases in IBD

04 Jul 2018

Use of antitumour necrosis factor (anti-TNF) agents in patients with inflammatory bowel disease (IBD) appears to be associated with an increased likelihood of developing psoriasiform diseases, with the risk of palmoplantar pustulosis most pronounced in males and younger patients, according to a study.

Drawing data from the Korea National Health Insurance Claim Data, researchers looked at 5,428 IBD patients treated with any anti‐TNF agent for >6 months (anti‐TNF group) and 10,856 matched controls who had never taken anti‐TNF agents (control group).

Psoriasis occurred with significantly greater frequency in the anti‐TNF vs control group (36.8 vs 14.5 per 10,000 person‐years). Use of anti-TNF was associated with a more than twofold increase in the risk of developing psoriasis (hazard ratio [HR], 2.357; 95 percent CI, 1.668–3.331).

Moreover, the anti-TNF group had greater risks of palmoplantar pustulosis (HR, 9.355; 2.754–31.780) and psoriatic arthritis (HR, 2.926; 1.640–5.218).

When analyses were stratified according to IBD subtypes, anti-TNF agent use was associated with a heightened risk of psoriasis in both Crohn’s disease (HR, 2.549; 1.658–3.920) and ulcerative colitis (HR, 2.105; 1.155–3.836).

Of note, the risk of palmoplantar pustulosis was markedly higher in subgroups of male (HR, 19.682; 3.867–100.169) and younger (aged 10–39 years; HR, 14.318; 2.915–70.315) patients exposed to anti-TNF agents.

The present data underscore the need for evaluating paradoxical psoriasiform diseases carefully when prescribing or considering anti‐TNF agents for IBD patients, as researchers pointed out. More studies are warranted to characterize the predictive factors for this phenomenon.

Editor's Recommendations
Most Read Articles
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
11 Nov 2016
Non-purulent cellulitis and cutaneous abscesses, despite both belonging to the spectrum of skin and soft-tissue infections, are aetiologically different, a new study reports. Further, atypical bacteria may be present in cellulitis patients, indicating novel disease mechanisms.
05 Jan 2017
Olumacostat glasaretil (OG) appears to be effective and is well tolerated in patients with moderate to severe facial acne vulgaris, suggesting the need for further development, according to a new study.
Tristan Manalac, 10 Mar 2018
Cost of treatment is a major driver of patients’ primary nonadherence to acne medication, according to a recent study. Physicians who openly discuss medications costs and provide a plan of action in case patients are unable to fill prescriptions may improve treatment adherence.